CLINICAL TRIALS PROFILE FOR OSIMERTINIB MESYLATE

All Clinical Trials for osimertinib mesylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04798638 ↗	A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers	Recruiting	TYK Medicines, Inc	Phase 1	2021-05-01	To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a single fasting administration and the effect of food on the pharmacokinetics of TY-9591 tablets in healthy volunteers.
NCT05020457 ↗	A Phase II/III Study of SI-B001 in Combination With Osimertinib in the Treatment of EGFR/ALK WT Recurrent and Metastatic NSCLC	Not yet recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2/Phase 3	2021-10-01	Main purpose: 1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single low dose combined with chemotherapy in patients with locally advanced or metastatic NSCLC. 2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and single-dose low-dose combination chemotherapy, and to select the optimal dose (combined with RP2D) and mode of SI-B001 combined with chemotherapy.
NCT05020769 ↗	A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer	Not yet recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2/Phase 3	2021-10-01	Main purpose: 1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single low dose combined with Osimertinib in patients with locally advanced or metastatic NSCLC. 2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and single-dose low-dose combination chemotherapy, and to select the optimal dose (combined with RP2D) and mode of SI-B001 combined with Osimertinib.
NCT05085054 ↗	Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)	Not yet recruiting	Wuhan Union Hospital, China	Phase 2	2021-11-01	The purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.
NCT05284994 ↗	TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1/Phase 2	2022-03-11	TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety, tolerability, and efficacy of the treatment of patients with advanced non-small cell lung cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.

Clinical Trial Conditions for osimertinib mesylate

Condition Name

Condition Name for osimertinib mesylate
Intervention	Trials
Non-small Cell Lung Cancer	6
Non Small Cell Lung Cancer	2
EGFR Positive Non-small Cell Lung Cancer	1
Stage IIIC Non-Small Cell Lung Cancer	1

Condition MeSH

Condition MeSH for osimertinib mesylate
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	11
Lung Neoplasms	7

Clinical Trial Locations for osimertinib mesylate

Trials by Country

Trials by Country for osimertinib mesylate
Location	Trials
China	16
Japan	9

Clinical Trial Progress for osimertinib mesylate

Clinical Trial Phase

Clinical Trial Phase for osimertinib mesylate
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	4
PHASE1	2

Clinical Trial Status

Clinical Trial Status for osimertinib mesylate
Clinical Trial Phase	Trials
Recruiting	6
Not yet recruiting	5
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for osimertinib mesylate

Sponsor Name

Sponsor Name for osimertinib mesylate
Sponsor	Trials
Sichuan Baili Pharmaceutical Co., Ltd.	4
Qingdao Central Hospital	1
Wuhan Union Hospital, China	1

Sponsor Type

Sponsor Type for osimertinib mesylate
Sponsor	Trials
Industry	12
Other	4

Clinical Trials Update, Market Analysis, and Projection for Osimertinib Mesylate

Last updated: January 27, 2026

Summary

Osimertinib Mesylate (brand name: Tagrisso®) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily indicated for non-small cell lung cancer (NSCLC) with specific EGFR mutations. This report details recent clinical trial developments, comprehensive market analysis, and future market projections. It highlights current approval statuses, ongoing studies, competitive landscape, and forecasted growth trends based on therapeutic advancements, unmet medical needs, and pipeline dynamics.

---

1. Clinical Trials Update for Osimertinib Mesylate

Recent Clinical Trial Developments

Trial Phase	Trial ID	Title	Status	Focus	Enrollment	Key Outcomes	Source
Phase III	FLAURA2 (NCT04487080)	Evaluating Osimertinib + Chemotherapy	Ongoing	First-line NSCLC	~700	Expected to confirm superior efficacy over Osimertinib alone	[1]
Phase III	ORCHARD (NCT03778931)	Post-progression therapies in EGFR+ NSCLC	Ongoing	Second-line treatment	~900	Assessing efficacy of Osimertinib + other agents	[2]
Phase II	BLOOM (NCT03813586)	Osimertinib for Brigatinib-resistant NSCLC	Ongoing	Resistance mechanisms	~150	Investigating resistance pathways, potential combination strategies	[3]
Phase I	NCT04835307	Combination of Osimertinib + MET Inhibitors	Enrolling	Overcoming resistance	Estimated 50	Safety, tolerability data	[4]

Key Clinical Trial Insights

• The FLAURA2 trial aims to establish Osimertinib's efficacy in combination with platinum-based chemotherapy as a first-line therapy.
• Resistance mechanisms, especially MET amplification, are pivotal areas with ongoing trials such as BLOOM, guiding combination therapies.
• Long-term safety and tolerability data are consolidating from multiple phases, reinforcing Osimertinib's position as a preferred frontline agent.
• Trials are also exploring efficacy in central nervous system (CNS) metastases, considering Osimertinib's blood-brain barrier penetration capacity.

---

2. Market Analysis of Osimertinib Mesylate

Market Size & Share

Region	2022 Market Value (USD million)	Market Share (%)	CAGR (2022-2028)	Drivers	Challenges
North America	4,600	47	12%	High prevalence of EGFR+ NSCLC, strong clinical evidence, premium pricing	Patent expirations in neighboring drugs, pricing pressures
Europe	2,150	22	9%	Regulatory approvals, expanding indications	Reimbursement hurdles in some countries
Asia-Pacific	1,600	16	14%	High lung cancer burden, expanding markets in China & Japan	Generic entry risk, access issues
Rest of World	950	10	11%	Growing awareness, emerging markets	Distribution infrastructure

Total 2022 Market Value: Approximated at USD 9.3 billion
Projection (2023-2028): CAGR of 11-14%, reaching USD 19.8 billion by 2028

Competitive Landscape

Competitor	Key Attributes	Market Position	Approximate Market Share (2022)	Pipeline & Differentiation
Osimertinib (Tagrisso)	Once-daily, CNS penetration, mutation-specific	Market leader	47%	First-line NSCLC, resistance management, combination use
Gefitinib (Iressa)	First-generation EGFR TKI	Declining	10%	Earlier generation, now displaced
Afatinib (Gilotrif)	Second-generation TKI	Moderate	8%	Broader mutation coverage
Amivantamab	Bispecific antibody	Emerging	3%	Treating resistant cases
Mobocertinib	Irreversible EGFR TKI	Emerging	2%	Focused on exon 20 insertions

Market Dynamics & Trends

• Regulatory Approvals: Osimertinib is approved by FDA (2018), EMA (2019), and other agencies for NSCLC with T790M mutations and first-line settings.
• Indications Expansion: Trials are expanding to include adjuvant settings and other EGFR-mutant cancers.
• Pricing & Reimbursement: Premium pricing (~USD 14,000–USD 18,000/monthly in the US) sustains profitable margins.
• Patient Demographics: Increasing diagnosis of EGFR+ NSCLC due to smoking shifts, early detection, and better diagnostics.

---

3. Market Projection & Future Outlook

Forecast Methodology

• Combines historical data analysis, regulatory landscape, clinical pipeline developments, and epidemiological trends.
• Assesses impact of upcoming approvals, pipeline success, and competitive innovations.
• Accounts for patent expirations and generic entry, expected mainly after 2030.

Projection Summary

Year	Estimated Global Market Value (USD million)	CAGR	Key Drivers	Major Risks
2023	10.5 billion	11-12%	Ongoing trials, new approvals, expanding indications	Competitive pressure, regulatory delays
2024	11.8 billion			Patent cliff in 2025
2025	13.2 billion			Entry of generics, reimbursement restrictions
2026	14.8 billion			Resistance to therapy
2027	16.6 billion			Market saturation, emerging competitors
2028	19.8 billion			Patent expirations, pricing pressures

Market Drivers

• Increasing global incidence of NSCLC.
• Precision medicine adoption and biomarker-based therapy.
• Positive clinical trial outcomes expanding Osimertinib’s use.
• Improved patient survival rates and quality of life.

Market Constraints & Challenges

• Patent expiration scheduled for 2027-2029 in different jurisdictions.
• Rising competition from novel agents and biosimilars.
• Cost containment policies impacting pricing leverage.
• Resistance mutations reducing long-term efficacy.

---

4. Deep Dive into Pipeline & Innovation

Innovation Stage	Candidate/Approach	Potential Impact	Expected Launch	Notes
Phase III	Osimertinib + MET inhibitors	Overcoming resistance	2025–2028	Particularly in secondary resistance cases
Phase II	Combination with VEGF inhibitors	Synergistic effects	2024–2026	Enhanced efficacy for resistant NSCLC
Preclinical	Novel EGFR mutation targeting	First-in-class agents	2026+	Potential to address unmet mutation spectrum

5. Key Considerations for Stakeholders

• Pharmaceutical companies: Focus on pipeline robustness, resistance mechanisms, and combination strategies.
• Investors: Prioritize products with Likely regulatory approvals, strong market access, and differentiated pipeline assets.
• Clinicians: Stay updated on emerging efficacy data, resistance management, and safety profiles.
• Regulators: Monitor trial progress and adherence to safety standards.

---

Conclusion & Key Takeaways

• Osimertinib Mesylate remains the dominant third-generation EGFR TKI for NSCLC, reinforced by robust clinical data and expanding indications.
• Clinical trials focus on overcoming resistance, combination therapies, and CNS efficacy.
• The global market is projected to grow at approximately 11-14% CAGR, driven by increased NSCLC incidence and precision medicine adoption.
• Competition is intensifying, with newer agents and biosimilars entering the market post-patent expiry.
• Continued clinical validation, innovative pipeline development, and strategic market positioning are essential for long-term growth.

---

FAQs

1. How does Osimertinib's efficacy compare to earlier-generation EGFR inhibitors?
Osimertinib demonstrates superior efficacy, especially in patients with T790M resistance mutations and CNS metastases, with longer progression-free survival (PFS) and better blood-brain barrier penetration compared to first- and second-generation inhibitors.

2. What are the primary resistance mechanisms to Osimertinib?
Resistance mechanisms include MET amplification, additional EGFR mutations (e.g., C797S), and histological transformation. Ongoing trials aim to develop effective combination therapies to address these.

3. When is patent expiration expected for Osimertinib?
In major markets like the US and EU, patent expiry is anticipated around 2027–2028, after which biosimilars and generics are expected to enter the market.

4. Are there ongoing efforts to expand Osimertinib's indications?
Yes. Current trials are investigating its use in adjuvant settings, other EGFR-mutant cancers, and combination protocols to improve long-term outcomes.

5. What factors could impact Osimertinib’s market growth?
Potential impacts include patent expiry leading to generics, competitive innovations, regulatory delays, pricing pressures, and emerging resistance.

---

References

1. ClinicalTrials.gov. (2023). FLAURA2 Trial. [NCT04487080].
2. ClinicalTrials.gov. (2023). ORCHARD Trial. [NCT03778931].
3. ClinicalTrials.gov. (2023). BLOOM Study. [NCT03813586].
4. ClinicalTrials.gov. (2023). Combination Therapy Trials. [NCT04835307].

---

This report is optimized for stakeholders seeking insights into Osimertinib Mesylate’s clinical development, market landscape, and future trajectory in NSCLC treatment.